董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony B. Evnin | 男 | Director | 77 | 5.31万美元 | 未持股 | 2018-04-27 |
| Kenneth M. Bate | 男 | Director | 67 | 6.77万美元 | 未持股 | 2018-04-27 |
| John H. Johnson | 男 | Director | 60 | 未披露 | 未持股 | 2018-04-27 |
| Kenneth M. Bate | 男 | Director | 67 | 未披露 | 未持股 | 2018-04-27 |
| Robert C. Young | 男 | Director | 78 | 4.93万美元 | 未持股 | 2018-04-27 |
| Michael P. Bailey | 男 | Director,President and Chief Executive Officer | 52 | 136.87万美元 | 未持股 | 2018-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Matthew Dallas | -- | Chief Financial Officer | -- | 103.23万美元 | 未持股 | 2018-04-27 |
| Nikhil Mehta | -- | Senior Vice President of Regulatory and Quality Assurance | -- | 115.17万美元 | 未持股 | 2018-04-27 |
| Karuna Rubin | -- | Senior Vice President and General Counsel | -- | 未披露 | 未持股 | 2018-04-27 |
| Michael P. Bailey | 男 | Director,President and Chief Executive Officer | 52 | 136.87万美元 | 未持股 | 2018-04-27 |
| Michael N. Needle | 男 | Chief Medical Officer | 64 | 81.35万美元 | 未持股 | 2018-04-27 |
董事简历
中英对照 | 中文 | 英文- Anthony B. Evnin
-
2006年9月以来，Anthony B. Evnin担任我们的董事会成员。从2001年6月起，他担任Infinity Discovery的董事会成员，直到2006年9月与我们的前身公司合并。自1975年以来，他担任Venrock公司的合伙人，一家风险投资公司。他担任AVEO Pharmaceuticals的董事，一家上市生物制药公司。他也担任Constellation Pharmaceuticals and Juno Therapeutics的董事，这2家公司都是私营生物制药公司。他担任洛克菲勒大学的受托人，杰克逊实验室的受托人，普林斯顿大学的名誉董事，董事监督会成员和纪念斯隆-凯特琳癌症中心的管理者，纽约基因组中心的主任，艾伯特和玛丽。拉斯科尔基金的董事会成员。之前，在过去的5年的时间里，他担任以下上市生物制药公司的董事包括：Acceleron Pharma，CymaBay Therapeutics，Memory Pharmaceuticals Corp.，Sunesis， Icagen，and Pharmos Corporation。并且在此之前，过去的5年的时间里，他担任以下私人控股公司的董事，包括：Acceleron Pharma，Altea Therapeutics Corporation，，and Celladon Corporation；（这些公司都是生物制药公司）and Boston-Power，一家锂蓄电池生产公司。他拥有普林斯顿大学的化学A.B。和麻省理工学院的化学博士学位。
Anthony B. Evnin, Partner of Venrock, a venture capital firm focused on technology and health care sectors, since 1975. Mr. Evnin currently serves on the board of directors of AVEO Pharmaceuticals, Inc. Nasdaq and Infinity Pharmaceuticals, Inc. (Nasdaq), as well as on the Boards of two private companies. He was formerly a director of over 35 companies, both public and private, in the life sciences area, including Constellation Pharmaceuticals, Inc. (Nasdaq) and Juno Therapeutics, Inc. (nasdaq). He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University. He holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology. - 2006年9月以来，Anthony B. Evnin担任我们的董事会成员。从2001年6月起，他担任Infinity Discovery的董事会成员，直到2006年9月与我们的前身公司合并。自1975年以来，他担任Venrock公司的合伙人，一家风险投资公司。他担任AVEO Pharmaceuticals的董事，一家上市生物制药公司。他也担任Constellation Pharmaceuticals and Juno Therapeutics的董事，这2家公司都是私营生物制药公司。他担任洛克菲勒大学的受托人，杰克逊实验室的受托人，普林斯顿大学的名誉董事，董事监督会成员和纪念斯隆-凯特琳癌症中心的管理者，纽约基因组中心的主任，艾伯特和玛丽。拉斯科尔基金的董事会成员。之前，在过去的5年的时间里，他担任以下上市生物制药公司的董事包括：Acceleron Pharma，CymaBay Therapeutics，Memory Pharmaceuticals Corp.，Sunesis， Icagen，and Pharmos Corporation。并且在此之前，过去的5年的时间里，他担任以下私人控股公司的董事，包括：Acceleron Pharma，Altea Therapeutics Corporation，，and Celladon Corporation；（这些公司都是生物制药公司）and Boston-Power，一家锂蓄电池生产公司。他拥有普林斯顿大学的化学A.B。和麻省理工学院的化学博士学位。
- Anthony B. Evnin, Partner of Venrock, a venture capital firm focused on technology and health care sectors, since 1975. Mr. Evnin currently serves on the board of directors of AVEO Pharmaceuticals, Inc. Nasdaq and Infinity Pharmaceuticals, Inc. (Nasdaq), as well as on the Boards of two private companies. He was formerly a director of over 35 companies, both public and private, in the life sciences area, including Constellation Pharmaceuticals, Inc. (Nasdaq) and Juno Therapeutics, Inc. (nasdaq). He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University. He holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
- Kenneth M. Bate
-
Kenneth M. Bate，2010年9月加入公司董事会并担任薪酬委员会主席。现任独立顾问。从2009年5月到2012年1月他担任Archemix 公司（一家私人持有的生物科技公司，从事发现和开发适体疗法，治疗慢性和急性疾病）总裁和首席执行官。2011年3月他被选为Cubist Pharmaceuticals公司（一家生物制药公司）非执行董事长；从2006年到2009年4月在NITROMED公司（一家制药公司）担任多个职位，最近的职位包括总裁和首席执行官。从2002年到2005年他担任Millennium制药公司首席执行官，担任商业组织主管。加入Millennium制药公司之前，他联合创立了JSB合伙企业（为生物制药和生命科学公司提供银行和咨询服务）；从1990年到l996年他在Biogen公司（现为 Biogen Idec公司，一家生物技术公司）工作，一开始担任首席财务官，之后担任商业组织部主管，负责推出多发性硬化症业务。他持有威廉姆斯大学化学学士学位以及宾夕法尼亚大学沃顿商学院工商管理硕士学位。他现任两大公开上市公司（AVEO制药公司和立体派制药公司）董事，两大私人公司（Catabasis制药公司--一家生物制药公司和TransMedics公司--一家医疗器械公司）董事。
Kenneth M. Bate currently works as an independent consultant. Previously, Mr. Bate was the President and Chief Executive Officer of Archemix Corp., a privately-held biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009 he served in various positions at NitroMed, Inc., a publicly-held pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005 Mr. Bate served as Head of Commercial Operations and Chief Financial Officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996 Mr. Bate was employed with Biogen, Inc., a publicly-held biotechnology company, first as its Chief Financial Officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate currently serves as chairman of the board of directors of the following publicly-held biopharmaceutical companies: AVEO Pharmaceuticals, Inc., Genocea Biosciences, Inc. and Catabasis Pharmaceuticals, Inc. In addition, Mr. Bate currently serves on the board of directors of Epizyme, Inc., a publicly-held biopharmaceutical company. During the last five years, Mr. Bate also served as chairman of the board of directors of Cubist Pharmaceuticals, Inc. and as a director of BioMarin Pharmaceuticals, Inc. and Vanda Pharmaceuticals Inc., each a publicly-held biopharmaceutical company. Mr. Bate holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania. - Kenneth M. Bate，2010年9月加入公司董事会并担任薪酬委员会主席。现任独立顾问。从2009年5月到2012年1月他担任Archemix 公司（一家私人持有的生物科技公司，从事发现和开发适体疗法，治疗慢性和急性疾病）总裁和首席执行官。2011年3月他被选为Cubist Pharmaceuticals公司（一家生物制药公司）非执行董事长；从2006年到2009年4月在NITROMED公司（一家制药公司）担任多个职位，最近的职位包括总裁和首席执行官。从2002年到2005年他担任Millennium制药公司首席执行官，担任商业组织主管。加入Millennium制药公司之前，他联合创立了JSB合伙企业（为生物制药和生命科学公司提供银行和咨询服务）；从1990年到l996年他在Biogen公司（现为 Biogen Idec公司，一家生物技术公司）工作，一开始担任首席财务官，之后担任商业组织部主管，负责推出多发性硬化症业务。他持有威廉姆斯大学化学学士学位以及宾夕法尼亚大学沃顿商学院工商管理硕士学位。他现任两大公开上市公司（AVEO制药公司和立体派制药公司）董事，两大私人公司（Catabasis制药公司--一家生物制药公司和TransMedics公司--一家医疗器械公司）董事。
- Kenneth M. Bate currently works as an independent consultant. Previously, Mr. Bate was the President and Chief Executive Officer of Archemix Corp., a privately-held biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009 he served in various positions at NitroMed, Inc., a publicly-held pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005 Mr. Bate served as Head of Commercial Operations and Chief Financial Officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996 Mr. Bate was employed with Biogen, Inc., a publicly-held biotechnology company, first as its Chief Financial Officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate currently serves as chairman of the board of directors of the following publicly-held biopharmaceutical companies: AVEO Pharmaceuticals, Inc., Genocea Biosciences, Inc. and Catabasis Pharmaceuticals, Inc. In addition, Mr. Bate currently serves on the board of directors of Epizyme, Inc., a publicly-held biopharmaceutical company. During the last five years, Mr. Bate also served as chairman of the board of directors of Cubist Pharmaceuticals, Inc. and as a director of BioMarin Pharmaceuticals, Inc. and Vanda Pharmaceuticals Inc., each a publicly-held biopharmaceutical company. Mr. Bate holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania.
- John H. Johnson
-
John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. - John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
- John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization.
- Kenneth M. Bate
-
Kenneth M. Bate自2007年12月以来曾担任董事。他目前是一个独立的顾问。之前，他从2009年4月到2011年12月是一个私人持有的生物制药公司Archemix公司的总裁兼首席执行官。从2006年到2009年4月，他在一家公共制药公司NitroMed有限公司担任过各种职务；最近的职务是总裁兼首席执行官。他从2002年到2005年担任一家生物制药公司千禧制药公司的商业运营负责人和首席财务官。在加入千禧制药之前，他共同创立JSB Partners有限责任公司；该公司是一家银行和咨询服务公司，专注于生物制药和生命科学。他从1990年到1996年被一家公共生物科技公司Biogen有限公司雇佣，起初担任首席财务官，后担任商业组织负责人，负责启动其多发性硬化症业务；该公司现为百健艾迪（Biogen Idec）有限公司。他目前担任卡毕斯特制药有限公司董事会主席且在BioMarin制药有限公司董事会任职；这两家公司都是公共生物制药公司。在过去的五年里，他担任一家私营医疗设备公司TransMedics有限公司董事。他最近加入一家私人生物制药公司Catabasis制药有限公司董事会。他拥有威廉姆斯学院化学学士学位及宾夕法尼亚大学沃顿商学院医学文学士学位。
Kenneth M. Bate,has served as a director since December 2007. He is currently an independent consultant. Mr. Bate currently serves on the boards of Catabasis Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc., Genocea Biosciences, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc., each a public biopharmaceutical company. During the last five years, Mr. Bate also served as chairman of the board of Cubist Pharmaceuticals, Inc. and as a director of BioMarin Pharmaceutical Inc., each a public biopharmaceutical company. Previously, Mr. Bate was the president and chief executive officer of Archemix Corp., a private biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009 he served in various positions at NitroMed, Inc., a public pharmaceutical company, most recently as president and chief executive officer. From 2002 to 2005 Mr. Bate served as head of commercial operations and chief financial officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996 Mr. Bate was employed with Biogen, Inc., a public biotechnology company, first as its chief financial officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. He holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania. - Kenneth M. Bate自2007年12月以来曾担任董事。他目前是一个独立的顾问。之前，他从2009年4月到2011年12月是一个私人持有的生物制药公司Archemix公司的总裁兼首席执行官。从2006年到2009年4月，他在一家公共制药公司NitroMed有限公司担任过各种职务；最近的职务是总裁兼首席执行官。他从2002年到2005年担任一家生物制药公司千禧制药公司的商业运营负责人和首席财务官。在加入千禧制药之前，他共同创立JSB Partners有限责任公司；该公司是一家银行和咨询服务公司，专注于生物制药和生命科学。他从1990年到1996年被一家公共生物科技公司Biogen有限公司雇佣，起初担任首席财务官，后担任商业组织负责人，负责启动其多发性硬化症业务；该公司现为百健艾迪（Biogen Idec）有限公司。他目前担任卡毕斯特制药有限公司董事会主席且在BioMarin制药有限公司董事会任职；这两家公司都是公共生物制药公司。在过去的五年里，他担任一家私营医疗设备公司TransMedics有限公司董事。他最近加入一家私人生物制药公司Catabasis制药有限公司董事会。他拥有威廉姆斯学院化学学士学位及宾夕法尼亚大学沃顿商学院医学文学士学位。
- Kenneth M. Bate,has served as a director since December 2007. He is currently an independent consultant. Mr. Bate currently serves on the boards of Catabasis Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc., Genocea Biosciences, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc., each a public biopharmaceutical company. During the last five years, Mr. Bate also served as chairman of the board of Cubist Pharmaceuticals, Inc. and as a director of BioMarin Pharmaceutical Inc., each a public biopharmaceutical company. Previously, Mr. Bate was the president and chief executive officer of Archemix Corp., a private biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009 he served in various positions at NitroMed, Inc., a public pharmaceutical company, most recently as president and chief executive officer. From 2002 to 2005 Mr. Bate served as head of commercial operations and chief financial officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996 Mr. Bate was employed with Biogen, Inc., a public biotechnology company, first as its chief financial officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. He holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania.
- Robert C. Young
-
Robert C. Young 自2009年7月以来曾担任董事。他是专注于癌症中心生产力、医疗质量和卫生政策的咨询提供者服务红十字青少年医学的总裁；该机构由他建立于2009年7月。他从2007年到2009年担任福克斯蔡斯癌症中心主任；从1989年到2007年任总裁兼首席执行官。他曾是美国临床肿瘤学会（ASCO）、美国癌症协会和国际妇科癌症协会总裁以及国家癌症研究所科学咨询委员会主席和综合癌症网络主席。他是肿瘤时代的编辑委员会的主席。从2002年7月到2002年5月，他曾在一家公共医药科技公司西氏医药服务有限公司董事会任职；从2005年11月到2012年7月在人类基因组科学公司董事会任职。在过去的五年里，他担任堪萨斯癌症中心科学、印第安纳州癌症中心和俄亥俄州立大学癌症中心的咨询委员会成员。他持有俄亥俄州立大学动物学理学士学位和康奈尔大学医学院医学博士学位；在委员会取得内科医学、血液学和医疗肿瘤学专业认证。
Robert C. Young, M.D.,has served as a director since July 2009. Dr. Young is president of RCY Medicine, a consulting company focused on cancer center productivity, health care quality and health policy which he founded in July 2009. From 2007 to 2009 Dr. Young served as chancellor of Fox Chase Cancer Center and as president and chief executive officer from 1989 to 2007. Dr. Young is a past president of the American Society of Clinical Oncology ASCO, the American Cancer Society and the International Gynecologic Cancer Society and past chairman of the board of scientific advisors of the National Cancer Institute and is past chairman of the National Comprehensive Cancer Network. Dr. Young serves as chairman of the editorial board of Oncology Times. Dr. Young served on the board of directors of West Pharmaceutical Services, Inc., a public pharmaceutical technology company, from July 2002 to May 2012 and on the board of directors of Human Genome Sciences, Inc., a biopharmaceutical company, from November 2005 to July 2012. During the last five years, Dr. Young has served as a member of the scientific advisory boards of the Kansas Cancer Center, the Indiana Cancer Center and the Ohio State Cancer Center. Dr. Young holds a B.Sc. in zoology from The Ohio State University and an M.D. from Cornell University Medical College and is board certified in Internal Medicine, Hematology and Medical Oncology. - Robert C. Young 自2009年7月以来曾担任董事。他是专注于癌症中心生产力、医疗质量和卫生政策的咨询提供者服务红十字青少年医学的总裁；该机构由他建立于2009年7月。他从2007年到2009年担任福克斯蔡斯癌症中心主任；从1989年到2007年任总裁兼首席执行官。他曾是美国临床肿瘤学会（ASCO）、美国癌症协会和国际妇科癌症协会总裁以及国家癌症研究所科学咨询委员会主席和综合癌症网络主席。他是肿瘤时代的编辑委员会的主席。从2002年7月到2002年5月，他曾在一家公共医药科技公司西氏医药服务有限公司董事会任职；从2005年11月到2012年7月在人类基因组科学公司董事会任职。在过去的五年里，他担任堪萨斯癌症中心科学、印第安纳州癌症中心和俄亥俄州立大学癌症中心的咨询委员会成员。他持有俄亥俄州立大学动物学理学士学位和康奈尔大学医学院医学博士学位；在委员会取得内科医学、血液学和医疗肿瘤学专业认证。
- Robert C. Young, M.D.,has served as a director since July 2009. Dr. Young is president of RCY Medicine, a consulting company focused on cancer center productivity, health care quality and health policy which he founded in July 2009. From 2007 to 2009 Dr. Young served as chancellor of Fox Chase Cancer Center and as president and chief executive officer from 1989 to 2007. Dr. Young is a past president of the American Society of Clinical Oncology ASCO, the American Cancer Society and the International Gynecologic Cancer Society and past chairman of the board of scientific advisors of the National Cancer Institute and is past chairman of the National Comprehensive Cancer Network. Dr. Young serves as chairman of the editorial board of Oncology Times. Dr. Young served on the board of directors of West Pharmaceutical Services, Inc., a public pharmaceutical technology company, from July 2002 to May 2012 and on the board of directors of Human Genome Sciences, Inc., a biopharmaceutical company, from November 2005 to July 2012. During the last five years, Dr. Young has served as a member of the scientific advisory boards of the Kansas Cancer Center, the Indiana Cancer Center and the Ohio State Cancer Center. Dr. Young holds a B.Sc. in zoology from The Ohio State University and an M.D. from Cornell University Medical College and is board certified in Internal Medicine, Hematology and Medical Oncology.
- Michael P. Bailey
-
Michael P. Bailey，2013年6月以来一直是我们的首席商务官。他于2010年9月加入我们公司，成为我们的首席商务官直到2013年6月。在加入我们公司之前，他从2008年到2010年9月担任Synta制药公司高级业务开发副总裁和首席商业官。从1999年到2008年，他在英克隆工作，领导他们的商业组织；最近担任商业运营高级副总裁。在加入英克隆之前，他从1997年到1999年在基因泰克公司管理心血管发展组合。他从成为Smith-Kline Beecham的执行营销发展计划一份子而开始他在制药业的职业生涯；他从1992年到1997年在那里扮演过各种各样的商业角色，包括从事销售、战略规划、产品管理。他拥有圣劳伦斯大学心理学学士学位和圣母大学的商学院MBA国际营销硕士学位。
Michael P. Bailey,has served as our President and Chief Executive Officer and as a director since January 6 2015. Mr. Bailey joined our company in September 2010 as our Chief Commercial Officer and was named our Chief Business Officer in June 2013. Prior to joining our company, Mr. Bailey served as senior vice president, business development and chief commercial officer at Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of oncology medicines, from August 2008 to September 2010. From 1999 to 2008 Mr. Bailey worked at ImClone Systems Incorporated, a biopharmaceutical company focused on the development and commercialization of treatments for cancer patients. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX cetuximab across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA (ramucirumab) and PORTRAZZA (necitumumab). In addition, Mr. Bailey was a member of the strategic leadership committees for ImClone and its North American and worldwide partnerships and led its commercial organization, most recently as senior vice president of commercial operations. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., a biotechnology company, from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of Smith-Kline Beecham’s executive marketing development program, where he held a variety of commercial roles from 1992 to 1997 including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at the University of Notre Dame. - Michael P. Bailey，2013年6月以来一直是我们的首席商务官。他于2010年9月加入我们公司，成为我们的首席商务官直到2013年6月。在加入我们公司之前，他从2008年到2010年9月担任Synta制药公司高级业务开发副总裁和首席商业官。从1999年到2008年，他在英克隆工作，领导他们的商业组织；最近担任商业运营高级副总裁。在加入英克隆之前，他从1997年到1999年在基因泰克公司管理心血管发展组合。他从成为Smith-Kline Beecham的执行营销发展计划一份子而开始他在制药业的职业生涯；他从1992年到1997年在那里扮演过各种各样的商业角色，包括从事销售、战略规划、产品管理。他拥有圣劳伦斯大学心理学学士学位和圣母大学的商学院MBA国际营销硕士学位。
- Michael P. Bailey,has served as our President and Chief Executive Officer and as a director since January 6 2015. Mr. Bailey joined our company in September 2010 as our Chief Commercial Officer and was named our Chief Business Officer in June 2013. Prior to joining our company, Mr. Bailey served as senior vice president, business development and chief commercial officer at Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of oncology medicines, from August 2008 to September 2010. From 1999 to 2008 Mr. Bailey worked at ImClone Systems Incorporated, a biopharmaceutical company focused on the development and commercialization of treatments for cancer patients. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX cetuximab across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA (ramucirumab) and PORTRAZZA (necitumumab). In addition, Mr. Bailey was a member of the strategic leadership committees for ImClone and its North American and worldwide partnerships and led its commercial organization, most recently as senior vice president of commercial operations. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., a biotechnology company, from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of Smith-Kline Beecham’s executive marketing development program, where he held a variety of commercial roles from 1992 to 1997 including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at the University of Notre Dame.
高管简历
中英对照 | 中文 | 英文- Matthew Dallas
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Nikhil Mehta
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Karuna Rubin
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Michael P. Bailey
Michael P. Bailey，2013年6月以来一直是我们的首席商务官。他于2010年9月加入我们公司，成为我们的首席商务官直到2013年6月。在加入我们公司之前，他从2008年到2010年9月担任Synta制药公司高级业务开发副总裁和首席商业官。从1999年到2008年，他在英克隆工作，领导他们的商业组织；最近担任商业运营高级副总裁。在加入英克隆之前，他从1997年到1999年在基因泰克公司管理心血管发展组合。他从成为Smith-Kline Beecham的执行营销发展计划一份子而开始他在制药业的职业生涯；他从1992年到1997年在那里扮演过各种各样的商业角色，包括从事销售、战略规划、产品管理。他拥有圣劳伦斯大学心理学学士学位和圣母大学的商学院MBA国际营销硕士学位。
Michael P. Bailey,has served as our President and Chief Executive Officer and as a director since January 6 2015. Mr. Bailey joined our company in September 2010 as our Chief Commercial Officer and was named our Chief Business Officer in June 2013. Prior to joining our company, Mr. Bailey served as senior vice president, business development and chief commercial officer at Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of oncology medicines, from August 2008 to September 2010. From 1999 to 2008 Mr. Bailey worked at ImClone Systems Incorporated, a biopharmaceutical company focused on the development and commercialization of treatments for cancer patients. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX cetuximab across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA (ramucirumab) and PORTRAZZA (necitumumab). In addition, Mr. Bailey was a member of the strategic leadership committees for ImClone and its North American and worldwide partnerships and led its commercial organization, most recently as senior vice president of commercial operations. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., a biotechnology company, from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of Smith-Kline Beecham’s executive marketing development program, where he held a variety of commercial roles from 1992 to 1997 including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at the University of Notre Dame.- Michael P. Bailey，2013年6月以来一直是我们的首席商务官。他于2010年9月加入我们公司，成为我们的首席商务官直到2013年6月。在加入我们公司之前，他从2008年到2010年9月担任Synta制药公司高级业务开发副总裁和首席商业官。从1999年到2008年，他在英克隆工作，领导他们的商业组织；最近担任商业运营高级副总裁。在加入英克隆之前，他从1997年到1999年在基因泰克公司管理心血管发展组合。他从成为Smith-Kline Beecham的执行营销发展计划一份子而开始他在制药业的职业生涯；他从1992年到1997年在那里扮演过各种各样的商业角色，包括从事销售、战略规划、产品管理。他拥有圣劳伦斯大学心理学学士学位和圣母大学的商学院MBA国际营销硕士学位。
- Michael P. Bailey,has served as our President and Chief Executive Officer and as a director since January 6 2015. Mr. Bailey joined our company in September 2010 as our Chief Commercial Officer and was named our Chief Business Officer in June 2013. Prior to joining our company, Mr. Bailey served as senior vice president, business development and chief commercial officer at Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of oncology medicines, from August 2008 to September 2010. From 1999 to 2008 Mr. Bailey worked at ImClone Systems Incorporated, a biopharmaceutical company focused on the development and commercialization of treatments for cancer patients. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX cetuximab across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA (ramucirumab) and PORTRAZZA (necitumumab). In addition, Mr. Bailey was a member of the strategic leadership committees for ImClone and its North American and worldwide partnerships and led its commercial organization, most recently as senior vice president of commercial operations. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., a biotechnology company, from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of Smith-Kline Beecham’s executive marketing development program, where he held a variety of commercial roles from 1992 to 1997 including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at the University of Notre Dame.
- Michael N. Needle
Michael N. Needle， 2013年4月起，他成为Array首席医药官；2012年4月至2013年3月，在加入Array之前，他在Multiple Myeloma Research Foundation and Consortium担任Multiple Myeloma Research Foundation and Consortium；2004年3月至2010年4月，他在Celgene多个部门担任副总裁，其中包括临床肿瘤研究和发展部、医药策略商务发展部以及儿科策略部；2000年4月至2004年2月，他在ImClone Systems Incorporated临床事务部担任副总裁。1993年至2010年和2010年至2013年这两段时期，他分别宾夕法尼亚大学和哥伦比亚大学任教。
Michael N. Needle was appointed Chief Medical Officer in January 2015. Dr. Needle has more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. This includes central roles in the development of oncology and hematology drugs, including Erbitux® cetuximab, Revlimid® (lenalidomide) and Pomalyst® (pomolidimide). He most recently served as Chief Medical Officer for Array BioPharma Inc., a biopharmaceutical company, from April 2013 to September 2014. Prior to Array, Dr. Needle was Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF), a research organization, from April 2012 to April 2013. From April 2010 to April 2012 Dr. Needle was Assistant Professor of Pediatrics at the College of Physicians and Surgeons of Columbia University. Previously, he held multiple Vice President level positions at Celgene Corporation, a biotechnology company, in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy from March 2004 to April 2010. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone from April 2000 to February 2004. Dr. Needle received his fellowship in Pediatric Hematology/Oncology at the Children’s Hospital Medical Center, the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and received his medical degree from SUNY Downstate Medical Center, in Brooklyn, New York.- Michael N. Needle， 2013年4月起，他成为Array首席医药官；2012年4月至2013年3月，在加入Array之前，他在Multiple Myeloma Research Foundation and Consortium担任Multiple Myeloma Research Foundation and Consortium；2004年3月至2010年4月，他在Celgene多个部门担任副总裁，其中包括临床肿瘤研究和发展部、医药策略商务发展部以及儿科策略部；2000年4月至2004年2月，他在ImClone Systems Incorporated临床事务部担任副总裁。1993年至2010年和2010年至2013年这两段时期，他分别宾夕法尼亚大学和哥伦比亚大学任教。
- Michael N. Needle was appointed Chief Medical Officer in January 2015. Dr. Needle has more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. This includes central roles in the development of oncology and hematology drugs, including Erbitux® cetuximab, Revlimid® (lenalidomide) and Pomalyst® (pomolidimide). He most recently served as Chief Medical Officer for Array BioPharma Inc., a biopharmaceutical company, from April 2013 to September 2014. Prior to Array, Dr. Needle was Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF), a research organization, from April 2012 to April 2013. From April 2010 to April 2012 Dr. Needle was Assistant Professor of Pediatrics at the College of Physicians and Surgeons of Columbia University. Previously, he held multiple Vice President level positions at Celgene Corporation, a biotechnology company, in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy from March 2004 to April 2010. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone from April 2000 to February 2004. Dr. Needle received his fellowship in Pediatric Hematology/Oncology at the Children’s Hospital Medical Center, the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and received his medical degree from SUNY Downstate Medical Center, in Brooklyn, New York.